Smoking cessation guidelines - 2008;Diretrizes para cessação do tabagismo - 2008

Jornal Brasileiro de Pneumologia

Volumn 34, Issue 10, 2008, Pages 845-880

  Reichert, Jonatas ^a,m   De Araújo, Alberto José ^b,c,d   Gonçalves, Cristina Maria Cantarino ^e,f   Godoy, Irma ^g,h   Chatkin, José Miguel ⁱ   Sales, Maria Da Penha Uchoa ^j   De Almeida Santos, Sergio Ricardo Rodrigues ^k,l  

^a Brazilian Thoracic Society   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^f Niterói Municipal Program for Smoking Control   (Brazil)

^g Department of Pulmonology ^*  (Brazil)

^h SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

ⁱ PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^j Hospital Messejana   (Brazil)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l Paulista Thoracic Society Commission on Smoking   (Brazil)

^m NONE   (Brazil)

more..

Author keywords

Guideline; Smoking cessation methods; Smoking adverse effects

Indexed keywords

EID: 56549115639     PISSN: 18063713     EISSN: 18063713     Source Type: Journal    
DOI: 10.1590/s1806-37132008001000014     Document Type: Review

References (242)

1. The Cochrane Library [homepage on the Internet], [cited 2008 Aug 15] Evidence for healthcare decision-making. Cochrane Review. Wiley Interscience; 2008. Available from: http://www3.interscience.wiley.com/cgi-bin/mrwhome/ 106568753/HOME
2. Fiore M. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville Md: U.S. Dept. of Health and Human Services, Public Health Service, 2008.
3. Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3(3-4):235-41.
4. Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using selfreported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict. 1989;84(7):791-9.
5. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-27.
6. Halty LS, Hüttner MD, Netto IC, Santos VA, Martins G. Análise da utilização do questionário de tolerância de Fagerström (QTF) como instrumento de medida da dependência nicotlnica. J Pneumol. 2002;28(4):180-86.
7. American Psychiatric Association. Diagnostic and Statistical manual of mental disorders: DSM-IV. Washington: American Psychiatric Association, 1994.
8. Cottler LB, Schuckit MA, Heizer JE, Crowley T, Woody G, Nathan P, et al. The DSM-IV field trial for substance use disorders: major results. Drug Alcohol Depend. 1995;38(1):59-69; discussion 71-83.
9. Figueiredo VC, Szklo M, Szklo AS, Benowitz N, Lozana JA, Casado L, et al. Determinantes dos níveis de cotinina salivar: um estudo de base populacional no Brasil. Rev Saúde Pública 2007:41(6):954-962.
10. Pirkle JL, Flegal KM, Bemert JT, Brody DJ, Etzel RA, Maurer KR. Exposure of the US population to environmental tobacco smoke: the Third National Health and Nutrition Examination Survey, 1988 to 1991. JAMA. 1996;275(16): 1233-40.
11. Bemert JT, Harmon TL, Sosnoff CS, McGuffey JE. Use of cotinine immunoassay test strips for preclassifying urine samples from smokers and nonsmokers prior to analysis by LC-MS-MS. J Anal Toxicol. 2005;29(8):814-8.
12. Santos UP, Gannam S, Abe JM, Esteves PB, Freitas FM, Wakassa TB, et al. Emprego da determinação de monóxido de carbono no ar exalado para a detecção do consumo de tabaco. J Pneumol. 2001:27(5):231-236.
13. Chen K, Kandel DB. The natural history of drug use from adolescence to the mid-thirties in a general population sample. Am J Public Health. 1995;85(1):41-7.
14. Sobell LC, Sobell MB. Guiding self-change. In: Miller W. R, Heather N, editors. Treating addictive behaviors. Applied clinical psychology. New York: Plenum Press; 1998. p. 189-202.
15. DiClemente CC, Prochaska JO. Self-change and therapy change of smoking behavior: a comparison of processes of change in cessation and maintenance. Addict Behav. 1982;7(2):133-42.
16. Miller W, Rollnick S, editors. Entrevista Motivacional Preparando as pessoas para a mudança de comportamentos aditivos. Porto Alegre: Artmed; 2001. pp. 30-42.
17. Miller WR, Taylor CA. Relative effectiveness of bibliotherapy, individual and group self-control training in the treatment of problem drinkers. Addict Behav. 1980;5(1):13-24.
18. Miller WR, Benefield RG, Tonigan JS. Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles. J Consult Clin Psychol. 1993;61(3):455-61.
19. Najavits LM, Weiss RD. Variations in therapist effectiveness in the treatment of patients with substance use disorders: an empirical review. Addiction. 1994;89(6):679-88.
20. Fuentes-Pila JM, Calatayud P, López E, Castañeda B. La entrevista motivacional: llave del proceso de cambio en la dependencia nicotín-tabáquica. Trastornos Adictivos. 2005;7(3):153-65.
21. Cibanal Juan L., Arce Sánchez M, Carballal Balsa MC. Técnicas de comunicación y relación de ayuda en ciencias de la salud. Madrid: Elsevier, 2003.
22. Bandura A. Self-efficacy: the exercise of control. New York: W.H. Freeman, 1997.
23. Bandura A. Social foundations of thought and action: a social cognitive theory. Prentice-Hall series in social learning theory. Englewood Cliffs: Prentice-Hall, 1986.
24. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008;83(4):531-41.
25. Chatkin JM. The influence of genetics on nicotine dependence and the role of pharmacogenetics in treating the smoking habit. J Bras Pneumol. 2006;32(6):573-9.
26. Munafò M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res. 2004;6(4):583-97.
27. Lerman C, Patterson F, Berrettini W. Treating tobacco dependence: state of the science and new directions. J Clin Oncol. 2005 Jan 10;23(2):311-23.
28. Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol. 2008;75(1):178-95.
29. Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J. 2007;7(2):81-98.
30. Sardinha A, Oliva AD, D'Augustin J, Ribeiro F, Falcone EM. O. Intervenção Cognitivo-Comportamental com grupos para o abandono do cigarro. Rev Bras Ter Cogn. 2005;1(1):83-90.
31. Brasil. Ministério da Saúde. Ajudando seu paciente a deixar de fumar. Rio de Janeiro: INCA, 1997.
32. Ministério da Saúde. Instituto Nacional de Câncer. Coordenação de Prevenção e Vigilância. Abordagem e Tratamento do Fumante - Consenso 2001. Rio de Janeiro: MS/INCA.
33. Ministério da Saúde. Instituto Nacional de Câncer. Coordenação de Prevenção e Vigilância. Deixando de fumar sem mistérios: Manual do Participante. Rio de Janeiro: MS/INCA; 2004.
34. Ministério da Saúde. Instituto Nacional do Câncer. Coordenação Nacional de Controle do tabagismo e Prevenção Primária do Câncer. Deixando de Fumar sem Mistérios. Manual do Coordenador. Rio de Janeiro: MS/INCA 2005.
35. Knapp P, Bertolote JM, organizers. Prevenção da Recaída - um manual para pessoas com problemas pelo uso do álcool e de drogas. Porto Alegre: Artes Médicas; 1994.
36. Marlatt GA, Gordon JR. Prevenção da Recaída: Estratégias e Manutenção no Tratamento de Comportamentos Adictivos. Porto Alegre: Artes Médicas; 1993.
37. Fiore M. Treating tobacco use and dependence. Clinical practice guideline, [no. 18]. Rockville: U.S. Dept. of Health and Human Services, Public Health Service, 2000.
38. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008;(1):CD000146. Update of: Cochrane Database Syst Rev. 2004;(3):CD000146.
39. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55(5):281-99; quiz 322-3, 325.
40. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch lntem Med. 1999;159(17):2033-8.
41. Balfour DJ, Fagerström KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther. 1996;72(1):51-81.
42. Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction. 2004;99(5):634-40.
43. Le Foll B, George TP. Treatment of tobacco dependence: integrating recent progress into practice. CMAJ. 2007;177(11):1373-80. Erratum in: CMAJ. 2008 Mar 11;178(6):732.
44. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovem J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann lntem Med. 2004;140(6):426-33.
45. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD000146.
46. Bolliger CT, van Biljon X, Axelsson A. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. Respiration. 2007;74(2):196-201.
47. Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerström KO. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest. 1995;108(2):447-51.
48. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA. 1995;274(17):1353-8.
49. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2002;(4):CD000146. Update in: Cochrane Database Syst Rev. 2004;(3):CD000146.
50. Ferrero MB, Mezquita MA, García MT, editors. Manual de prevención y tratamiento del tabaquismo. Madrid: Ergon, Madrid; 2003.
51. Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes para Cessação do Tabagismo. J Bras Pneumol. 2004;30(2):S1-S76.
52. Rosemberg J, Rosemberg AM, Moraes MA. Nicotina: droga universal. Sao Paulo: Sao Paulo (Estado). Secretaria da Saude. Centro de Vigilancia Epidemiologica, 2003.
53. Fagerström K. New perspectives in the treatment of tobacco dependence. Monaldi Arch Chest Dis. 2003;60(3):179-83.
54. Hughes JR, Stead LF, LancasterT. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;(1):CD000031.
55. Balfour DJ. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract. 2001;55(1):53-7.
56. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs. 2002;62(Suppl 2):25-35.
57. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs. 2000;59(4): 1007-24.
58. Reichert J. Tratamento Farmacológico do Tabagismo. In: Viegas CA, editor. Tabagismo - do diagnóstico à saúde publica. São Paulo: Atheneu, 2007. p. 233-236.
59. Viegas CA, Reichert J. Tratamento Medicamentoso. J Bras Pneumol. 2004;30(supl.2) :S36-S40.
60. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. lnt J Clin Pract. 2006;60(5):571-6.
61. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474-7.
62. Etter JF. Cytisine forsmoking cessation:a literature review and a meta-analysis. Arch lntem Med. 2006;166(15): 1553-9.
63. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2007;(1):CD006103.
64. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.
65. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34(1):121-30.
66. Keating GM, Siddiqui MA. Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs. 2006;20(11):945-60.
67. Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA. 2008;299(10):1121-2.
68. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717-24.
69. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685-91.
70. McRobbie H, Lee M, Juniper Z. Non-nicotine pharmacotherapies for smoking cessation. Respir Med. 2005;99(10):1203-12.
71. Wagena EJ, Knipschild P, Zeegers MP. Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction. 2005;100(3):317-26.
72. Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ. 2008;336(7655):1223-7.
73. Prochazka AV, Kick S, Steinbrunn C, Miyoshi T, Fryer GE. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch lntem Med. 2004;164(20):2229-33.
74. Hall SM, Reus VI, Muñoz RF, Sees KL, Humfleet G, Hartz DT, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry. 1998;55(8):683-90.
75. Haggsträm FM, Chatkin JM, Sussenbach-Vaz E, Cesari DH, Fam CF, Fritscher CC. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulm Pharmacol Ther. 2006;19(3):205-9.
76. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch lntem Med. 2005;165(19):2286-92.
77. da Costa CL, Younes RN, Lourenço MT. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest. 2002;122(2):403-8.
78. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch lntem Med. 1998;158(18):2035-9.
79. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000058.
80. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2000;(2):CD000058. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD000058.
81. Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Database Syst Rev. 2005;(2):Update Software.
82. Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Database Syst Rev. 2000;(2):CD000191.
83. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007;(3):CD005353. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD005353.
84. David S, Lancaster T, Stead LF, Evins AE. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2006;(4):CD003086.
85. Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev. 2007;(2):CD002849. Achei esse: Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev. 2000;(4):CD002849.
86. Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev. 2000;(4):CD002849.
87. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53(2): 136-43.
88. Stead LF, Lancaster T. Nicobrevin for smoking cessation. Cochrane Database Syst Rev. 2006;(2):CD005990.
89. Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev. 2000;(2):CD001009.
90. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev. 2000;(2):CD000124.
91. Hajek P, Stead LF. Aversive smoking for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000546.
92. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;78(5):456-67. Erratum in: Clin Pharmacol Ther. 2006;79(4):396.
93. Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics. 2004;30(4):344-5.
94. Hughes JR, Shiffman S, Callas P, Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control. 2003;12(1):21-7.
95. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev. 2005;(3):CD001118.
96. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004;(4):CD000165. Review. Update in: Cochrane Database Syst Rev. 2008;(2):CD000165.
97. Gorin SS, Heck JE. Meta-analysis of the efficacy of tobacco counseling by health care providers. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2012-22.
98. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001007.
99. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001292.
100. Walters ST, Wright JA, Shegog R. A review of computer and Internet-based interventions for smoking behavior. Addict Behav. 2006;31(2):264-77.
101. Etter JF. Comparing the efficacy of two Internet-based, computer-tailored smoking cessation programs: a randomized trial. J Med Internet Res. 2005;7(1):e2.
102. Ussher M. Exercise interventions for smoking cessation. Cochrane Database Syst Rev. 2005;(1):CD002295.
103. White AR, Rampes H, Campbell JL. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev. 2006;(1):CD000009.
104. Abbot NC, Stead LF, White AR, Bames J, Ernst E. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev. 2000;(2):CD001008.
105. Bize R, Bumand B, Mueller Y, Comuz J. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev. 2005;(4):CD004705.
106. Zhu SH, Anderson CM, Tedeschi GJ, Rosbrook B, Johnson CE, Byrd M, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med. 2002;347(14):1087-93.
107. Stead LF, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2001;(2):CD002850.Update in: Cochrane Database Syst Rev. 2003;(1):CD002850.
108. Reichert VC, Seltzer V, Efferen LS, Kohn N. Women and tobacco dependence. Med Clin North Am. 2004;88(6):1467-81, x.
109. World Health Organization. Gender, Health and Tobacco - Tobacco Free Initiative. Geneva: WHO, 2003.
110. Rivera MP, Stover DE. Gender and lung cancer. Clin Chest Med. 2004;25(2):391-400.
111. Hirayama T. Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan. Br Med J (Clin Res Ed). 1981;282(6259):183-5.
112. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ. 1989;298(6667):165-8.
113. Perkins KA. Smoking cessation in women. Special considerations. CNS Drugs. 2001;15(5):391-411.
114. lschaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996;348(9026):498-505.
115. US. Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion. Women and smoking: a report of the Surgeon General. Rockville: U.S. Dept. of Health and Human Services, Public Health Service, Office of the Surgeon General, 2001.
116. Araujo AJ, Caldas N, Borges MT, Ortolan F, Cassabian L, Zoucas MA. Abordagem de populações especiais: tabagismo e mulher - razões para abordagem específica de gênero. In: Gigliotti A, Pressman S, organizers. Atualização no Tratamento do Tabagismo. Rio de Janeiro: Abe Saúde; 2006. p. 107-128.
117. US Center for Chronic Disease Prevention and Health Promotion. The Health benefits of smoking cessation: a report of the Surgeon General. DHHS publication, no. (CDC) 90-8416. Rockville: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1990.
118. Lumley J, Oliver SS, Chamberlain C, Oakley L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2004;(4):CD001055. Update of: Cochrane Database Syst Rev. 2000;(2):CD001055.
119. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000;55(12):987-99.
120. Halty LS, Hüttner MD, Netto 10, Fenker T, Pasqualine T, Lempek B, et al. Pesquisa sobre tabagismo entre médicos de Rio Grande, RS: prevalência e perfil do fumante. J Pneumol. 2002;28(2):77-83.
121. Guazzelli AC, Terra Filho M, Fiss E. Tabagismo entre médios da região do ABC Paulista. J Bras Pneumol. 2005;31(6):516-22.
122. Mirra AP, Rosemberg J. Inquérito sobre prevalência do tabagismo na classe médica brasileira. Rev Assoc Méd Bras. 1997;43(3):209-16.
123. Viegas CA, Andrade AP, Silvestre RS. Characteristics of smoking among physicians in the Federal District of Brazil. J Bras Pneumol. 2007;33(1):76-80.
124. Lotufo JP, editor. Tabagismo, uma doença pediátrica. São Paulo: Savier; 2007. p. 17-19.
125. Mannino DM, Siegel M, Husten C, Rose D, Etzel R. Environmental tobacco smoke exposure and health effects in children: results from the 1991 National Health Interview Survey. Tob Control. 1996;5(1):13-8.
126. Mannino DM, Moorman JE, Kingsley B, Rose D, Repace J. Health effects related to environmental tobacco smoke exposure in children in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med. 2001;155(1):36-41.
127. World Health Organization. International Consultation on Environmental Tobacco Smoke (ETS) and Child Health. Geneva: World Health Organization, 1999.
128. National Cancer Institute. Smoking, tobacco, and cancer program: 1985-1989 status report. NIH publication, no. 90-3107. Bethesda: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1990.
129. Samet JM, Tager IB, Speizer FE. The relationship between respiratory illness in childhood and chronic air-flow obstruction in adulthood. Am Rev Respir Dis. 1983;127(4):508-23.
130. Tager IB. Passive smoking-bronchial responsiveness and atopy. Am Rev Respir Dis. 1988; 138(3):507-9.
131. National Asthma Education and Prevention Program. Expert Panel report 3: guidelines for the diagnosis and management of asthma. NIH publication, no. 07-4051. Bethesda: National Institutes of Health, National Heart, Lung, and Blood Institute, 2007.
132. Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tob Control. 1994;3(3):242-247.
133. Bratzler DW, Oehlert WH, Austeile A. Smoking in the elderly-it's never too late to quit. J Okla State Med Assoc. 2002;95(3):185-91; quiz 192-3.
134. Williams CD, Lewis-Jack O, Johnson K, Adams-Campbell L. Environmental influences, employment status, and religious activity predict current cigarette smoking in the elderly. Addict Behav. 2001;26(2):297-301.
135. Kaplan MS, Newsom JT, McFarland BH. Older adults' contact with health practitioners: is there an association with smoking practices? J Gerontol A Biol Sci Med Sci. 2002;57(6):M343-6.
136. Maxwell CJ, Hirdes JP. The prevalence of smoking and implications for quality of life among the community-based elderly. Am J Prev Med. 1993;9(6):338-45.
137. Ishii T, Teramoto S, Miyashita A, Ishigatsubo Y, Kimura H, Kuwahira I, et al. Questionnaire on the attitude of the physicians in educating the elderly patients with chronic obstructive pulmonary disease about smoking cessation [Article in Japanese]. Nippon Ronen Igakkai Zasshi. 2002;39(3):308-13.
138. Tsoh JY, Humfleet GL, Muñoz RF, Reus VI, Hartz DT, Hall SM. Development of major depression after treatment for smoking cessation. Am J Psychiatry. 2000;157(3):368-74. Erratum in: Am J Psychiatry 2000;157(8):1359.
139. Dale LC, Olsen DA, Patten CA, Schroeder DR, Croghan IT, Hurt RD, et al. Predictors of smoking cessation among elderly smokers treated for nicotine dependence. Tob Control. 1997;6(3):181-7.
140. Lando H, Hennrikus D, McCarty M, Vessey J. Predictors of quitting in hospitalized smokers. Nicotine Tob Res. 2003;5(2):215-22.
141. Appel DW, Aldrich TK. Smoking cessation in the elderly. Clin Geriatr Med. 2003;19(1):77-100.
142. Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther. 1998;12(3):239-44.
143. Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes para Cessação do Tabagismo. J Bras Pneumol. 2004;30(2): S1-S76.
144. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131(2):446-52.
145. Molyneux A, Lewis S, Leivers U, Anderton A, Antoniak M, Brackenridge A, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. Thorax. 2003;58(6):484-8.
146. Simon JA, Carmody TP, Hudes ES, Snyder E, Murray J. Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med. 2003;114(7):555-62.
147. Rigotti NA, Amsten JH, McKool KM, Wood-Reid KM, Pasternak RC, Singer DE. Smoking by patients in a smoke-free hospital: prevalence, predictors, and implications. Prev Med. 2000;31(2 Pt 1):159-66.
148. Rigotti NA, Amsten JH, McKool KM, Wood-Reid KM, Singer DE, Pastemak RC. The use of nicotine-replacement therapy by hospitalized smokers. Am J Prev Med. 1999;17(4):255-9.
149. Rigotti NA, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2007;(3):CD001837.
150. Rigotti NA, McKool KM, Shiffman S. Predictors of smoking cessation after coronary artery bypass graft surgery. Results of a randomized trial with 5-year follow-up. Ann lntem Med. 1994;120(4):287-93.
151. Emmons KM, Goldstein MG, Roberts M, Cargill B, Sherman CB, Millman R, et al. The use of nicotine replacement therapy during hospitalization. Ann Behav Med. 2000;22(4):325-9.
152. Goodman MJ, Nadkami M, Schorling JB. The Natural History of Smoking Cessation Among Medical Patients in a Smoke-Free Hospital. Subst Abus. 1998;19(2):71-79.
153. Munafò M, Rigotti N, Lancaster T, Stead L, Murphy M. Interventions for smoking cessation in hospitalised patients: a systematic review. Thorax. 2001;56(8):656-63.
154. Reid R, Pipe A, Higginson L, Johnson K, D'Angelo MS, Cooke D, et al. Stepped care approach to smoking cessation in patients hospitalized for coronary artery disease. J Cardiopulm Rehabil. 2003;23(3):176-82.
155. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335(24): 1792-8. Erratum in: N Engl J Med. 2007;356(24):2554.
156. Lando H, Hennrikus D, McCarty M, Vessey J. Predictors of quitting in hospitalized smokers. Nicotine Tob Res. 2003;5(2):215-22.
157. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;72(6):1144-56.
158. Hughes JR, Kalman D. Do smokers with alcohol problems have more difficulty quitting? Drug Alcohol Depend. 2006;82(2):91-102.
159. Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann lntem Med. 2006;145(11):845-56.
160. Ratto LR, Menezes PR, Gulinelli A. Prevalence of tobacco use in individuals with severe mental illnesses, São Paulo, Brazil. Rev Saude Publica. 2007;41(4):510-6.
161. Morrell HE, Cohen LM, al'Absi M. Physiological and psychological symptoms and predictors in early nicotine withdrawal. Pharmacol Biochem Behav. 2008;89(3):272-8.
162. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115-21.
163. El-Guebaly N, Cathcart J, Currie S, Brown D, Gloster S. Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatr Serv. 2002;53(9):1166-70.
164. Tsoh JY, Humfleet GL, Muñoz RF, Reus VI, Hartz DT, Hall SM. Development of major depression after treatment for smoking cessation. Am J Psychiatry. 2000;157(3):368-74. Erratum in: Am J Psychiatry 2000;157(8):1359.
165. Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: a meta-analysis. J Consult Clin Psychol. 2003;71(4):657-63.
166. US. National Center for Chronic Disease Prevention and Health Promotion. The health consequences of smoking a report of the Surgeon General. [Atlanta, Ga.]: U.S. Public Health Service, National Center for Chronic Disease Prevention and Health Promotion, 2004.
167. Maity P, Biswas K, Roy S, Banerjee RK, Bandyopadhyay U. Smoking and the pathogenesis of gastroduodenal ulcer-recent mechanistic update. Mol Cell Biochem. 2003;253(1-2):329-38.
168. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther. 2005;21(8):921-31.
169. Mahid SS, Minor KS, Stevens PL, Galandiuk S. The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci. 2007;52(11):2897-903.
170. Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis. 2008;23;3:1.
171. HézodeC, Lonjon I, Roudot-Thoraval F, MavierJP, Pawlotsky JM, Zafrani ES, et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut. 2003;52(1):126-9.
172. Weinrieb RM, Lucey MR. Treatment of addictive behaviors in liver transplant patients. Liver Transpl. 2007;13(11 Suppl 2):S79-S82.
173. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care. 1999;22(11):1887-98.
174. Willi C, Bodenmann P, Ghali WA, Faris PD, Comuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2007;298(22):2654-64.
175. Vestergaard P. Smoking and thyroid disorders-a meta-analysis. Eur J Endocrinol. 2002;146(2):153-61.
176. Holm IA, Manson JE, Michels KB, Alexander EK, Willett WC, Utiger RD. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intem Med. 2005;165(14):1606-11.
177. Wong PK, Christie JJ, Wark JD. The effects of smoking on bone health. Clin Sci (Lond). 2007;113(5):233-41.
178. Benard A, Bonnet F, Tessier JF, Fossoux H, Dupon M, Mercie P, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS. 2007;21(7):458-68.
179. Rabe KF, Hurd S, Anzueto A, Bames PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-55.
180. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645-8.
181. Siroux V, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. Eur Respir J. 2000;15(3):470-7.
182. Ryu JH, Colby TV, Hartman TE, Vassallo R. Smoking-related interstitial lung diseases: a concise review. Eur Respir J. 2001;17(1):122-32.
183. McEwen A, Hajek P, McRobbie, West R. The health risk of smoking and benefits of stopping. In: McEwen A, editor. Manual of smoking cessation: a guide for counsellors and practitioners. Oxford: Blackwell Pub, 2006. p. 15-32.
184. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(6):1583-633.
185. National Institute on Drug Abuse. Relapse Prevention Package: Examines two effective relapse prevention models, the Recovery Training and Self-Help (RTSH) program and the Cue Extinction model. Bethesda: NIDA, 1993.
186. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390-5.
187. Catford JC, Nutbeam D. Smoking in hospitals. Lancet. 1983;2(8341):94-6.
188. Collins D, Lapsley H. The Economics of Tobacco Policy [monograph on the Internet]. Tobacco control factsheets Available from: http://www.globalink.org/ en/economics.shtml
189. Hurt RD, Berge KG, Offord KP, Leonard DA, Gerlach DK, Renquist CL, et al. The making of a smoke-free medical center. JAMA. 1989;261(1):95-7.
190. American Hospital Association. Smoking and hospitals are a bad matchl: policy development and implementation strategies for a smokefree environment. Chicago: American Hospital Association, 1988.
191. WHO. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER package. Geneva: World Health Organization, 2008.
192. World Health Organization - WHO [homepage on the Internet]. Geneve: WHO. [cited 2008 Aug 15], Code of practice on tobacco control for health professional organizations. Available from: http://www.who.int/tobacco/communications/ events/codeofpractice/en/
193. Laranjeira R, Ferreira MP. Como criar um hospital livre de cigarros. Rev Ass Med Bras. 1997;43(2):169-72.
194. Hughes JR. Why does smoking so often produce dependence? A somewhat different view. Tob Control. 2001;10(1):62-4.
195. Rondina RC, Botelho C. Silva AM, Gorayeb R. Características de personalidade e dependência nicotínica em universitários fumantes da UFMT. J Pneumol. 2003;29(1):21-7.
196. Black DW, Zimmerman M, Coryell WH. Cigarette smoking and psychiatric disorder in a community sample. Ann Clin Psychiatry. 1999;11(3):129-36.
197. Bejerot S, von Knorring L, Ekselius L. Personality traits and smoking in patients with obsessive-compulsive disorder. Eur Psychiatry. 2000;15(7):395-401.
198. Klesges RC, Eck LH, Isbell TR, Fulliton W, Hanson CL. Smoking status: effects on the dietary intake, physical activity, and body fat of adult men. Am J Clin Nutr. 1990;51(5):784-9.
199. Perkins KA, Epstein LH, Pastor S. Changes in energy balance following smoking cessation and resumption of smoking in women. J Consult Clin Psychol. 1990;58(1):121-5.
200. Gonçalves-Silva RM, Lemos-Santos MG, Botelho C. Influência do tabagismo no ganho ponderal, crescimento corporal, consumo alimentar e hídrico de ratos. J Pneumol. 1997;23(3):124-130.
201. Glauser SC, Glauser EM, Reidenberg MM, Rusy BF, Tallarida RJ. Metabolic changes associated with the cessation of cigarette smoking. Arch Environ Health. 1970;20(3):377-81.
202. Moffatt RJ, Owens SG. Cessation from cigarette smoking: changes in body weight, body composition, resting metabolism, and energy consumption. Metabolism. 1991;40(5):465-70.
203. Lemos-Santos MG, Gonçalves-Silva RM, Botelho C. Tabagismo, composição corporal, distribuição da adiposidade e ingestão alimentar em fumantes, não fumantes e ex-fumantes. F Med. 2000;119(3):23-31.
204. Eliasson B, Hjalmarson A, Kruse E, Landfeldt B, Westin A . Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine Tob Res. 2001;3(3):249-55.
205. Hatsukami DK, Kotlyar M, Allen S, Jensen J, Li S, Le C, et al. Effects of cigarette reduction on cardiovascular risk factors and subjective measures. Chest. 2005;128(4):2528-37.
206. Prescott E, Scharling H, Osler M, Schnohr P. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health. 2002;56(9):702-6.
207. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. 1998;316(7137):1043-7.
208. Godtfredsen NS, Osler M, Vestbo J, Andersen I, Prescott E. Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study. J Epidemiol Community Health. 2003;57(6):412-6.
209. Bjartveit K, Tverdal A. Health consequences of smoking 1-4 cigarettes per day. Tob Control. 2005;14(5):315-20.
210. Rodu B, Godshall WT. Tobacco harm reduction: an alternative cessation strategy for inveterate smokers. Harm Reduct J. 2006;3:37.
211. Tomar SL. Epidemiologic perspectives on smokeless tobacco marketing and population harm. Am J Prev Med. 2007;33(6 Suppl):S387-S97.
212. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control. 2005;16(4):347-58.
213. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368(9536):647-58.
214. Godtfredsen NS, Holst C, Prescott E, Vestbo J, Osler M. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol. 2002;156(11):994-1001.
215. Hecht SS, Murphy SE, Carmella SG, Zimmerman CL, Losey L, Kramarczuk I, et al. Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst. 2004;96(2):107-15.
216. Hecht SS, Murphy SE, Carmella SG, Li S, Jensen J, Le C, et al. Similar uptake of lung carcinogens by smokers of regular, light, and ultralight cigarettes. Cancer Epidemiol Biomarkers Prev. 2005;14(3):693-8. Erratum in: Cancer Epidemiol Biomarkers Prev. 2006;15(8):1568.
217. Cogliano V, Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol. 2004;5(12):708.
218. Rodu B, Cole P. Smokeless tobacco use and cancer of the upper respiratory tract. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(5):511-5.
219. Rennard SI, Daughton D, Fujita J, Oehlerking MB, Dobson JR, Stahl MG, et al. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J. 1990;3(7):752-9.
220. Rennard SI, Umino T, Millatmal T, Daughton DM, Manouilova LS, Ullrich FA, et al. Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device that primarily heats tobacco. Nicotine Tob Res. 2002;4(4):467-76.
221. Jiménez-Ruiz C, Solano S, Viteri SA, Ferrero MB, Torrecilla M, Mezquita MH. Harm reduction - a treatment approach for resistant smokers with tobacco-related symptoms. Respiration. 2002;69(5):452-5.
222. Stein MD, Weinstock MC, Herman DS, Anderson BJ. Respiratory symptom relief related to reduction in cigarette use. J Gen lntem Med. 2005;20(10):889-94.
223. Simmons MS, Connett JE, Nides MA, Lindgren PG, Kleerup EC, Murray RP, et al. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. Eur Respir J. 2005;25(6):1011-7.
224. Godtfredsen NS, Vestbo J, Osier M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax. 2002;57(11):967-72.
225. Stratton K, Shetty P, Wallace R, Bondurant S, editors. Clearing the Smoke: assessing the science base for harm reduction. Washington, DC: Institute of Medicine, National Academies Press, 2001.
226. McNeill A. Harm reduction. BMJ. 2004;328(7444):885-7.
227. Foulds J, Ramstrom L, Burke M, Fagerström K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control. 2003;12(4):349-59.
228. Biener L, Bogen K, Connolly G. Impact of corrective health information on consumers' perceptions of "reduced exposure" tobacco products. Tob Control. 2007;16(5):306-11.
229. Fagerström KO, Hughes JR, Rasmussen T, Callas PW. Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tob Control. 2000;9(3):327-33.
230. Slade J, Connolly GN, Lymperis D. Eclipse: does it live up to its health claims? Tob Control. 2002;11 Suppl 2:ii64-70.
231. Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. Tob Control. 2006;15(6):472-80.
232. Tonnesen P, Carrozzi L, Fagerström KO, Gratziou C, Jimenez-Ruiz C, Nardini S, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J. 2007;29(2):390-417.
233. Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev. 2007;(3):CD005231.
234. Brasil. Instituto Nacional do Câncer. Ação global para o controle do tabaco. Primeiro Tratado Internacional de Saúde Pública. Brasília: Ministério da Saúde, 2002.
235. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man. Lyon: International Agency for Research on Cancer, 1986.
236. U.S. Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006.
237. Olds DL, Henderson CR Jr, Tatelbaum R. Intellectual impairment in children of women who smoke cigarettes during pregnancy. Pediatrics. 1994;93(2):221-7. Erratum in: Pediatrics 1994;93(6 Pt 1):973.
238. DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children's health. Pediatrics. 2004;113(4 Suppl):1007-15.
239. Johnson JG, Cohen P, Pine DS, Klein DF, Kasen S, Brook JS. Association between cigarette smoking and anxiety disorders during adolescence and early adulthood. JAMA. 2000;284(18):2348-51.
240. Naeye RL. Cognitive and behavioral abnormalities in children whose mothers smoked cigarettes during pregnancy. J Dev Behav Pediatr. 1992;13(6):425-8.
241. Vineis P, Airoldi L, Veglia F, Olgiati L, Pastorelli R, Autrup H, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ. 2005;330(7486):277.
242. Eisner MD, Balmes J, Katz PP, Trupin L, Yelin EH, Blanc PD. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health. 2005;4(1):7.